Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleUk· December 10, 2025

FTSE 100 LIVE: Stocks mixed as traders await US Federal Reserve interest rate decision

View original at uk.finance.yahoo.com
FTSE 100 LIVE: Stocks mixed as traders await US Federal Reserve interest rate decision The FTSE 100 (^FTSE) pushed higher on Wednesday morning while European stocks were mixed as traders awaited the latest decision on interest rates from the Federal Reserve…
Opening lines of the source · Uk · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The announcement of the November budget and potential changes to stamp duty and council tax caused would-be buyers to wait

    80% confidence
  • There will be dissents in both a hawkish and dovish direction, and the statement and press conference will signal that the hurdle is relatively high for another cut in early 2026

    80% confidence
  • On track to meet pre-tax profit guidance of £450m for the year

    80% confidence
  • A December rate cut was not a foregone conclusion – far from it

    80% confidence
  • Oracle may not have substantial weight in the S&P 500 or NAS100 to move the index on its own, but what they detail on capex intentions and future funding plans could resonate across the AI space

    80% confidence
  • A range of factors are pushing up silver including a shortage fear as demand rises

    80% confidence
  • The group is expanding its use of artificial intelligence, which is a great opportunity

    80% confidence
  • Early signs are positive for summer 2026, with booked revenue well ahead in what remains a challenging operating environment

    80% confidence
  • When interest rates are cut, that naturally shifts demand toward assets viewed as stores of value, including silver

    80% confidence
  • Earnings are set to grow between 7% to 10% over the year ahead, while revenues are expected to rise by a slower 2% to 4%

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com